TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Central Nervous System

CNS remains among the most active and challenging realms of drug development, focused on significant and growing market opportunities in categories as diverse as Treatment-Resistant Depression and Alzheimer’s Disease. In 2021, we expect data readouts in novel areas such as psilocybin therapeutics and closely watched trials involving anti-amyloid, anti-tau and immune-modulatory therapeutics.

What we’re watching

  • 6 Alzheimer’s Disease (AD) trial readouts in 1H21
  • The FDA decision on potential approval for aducanumab for Alzheimer’s (1Q21)
  • Anti-Tau data
  • COMP360 / Psilocybin 2H21 data in Treatment-Resistant Depression (TRD)
  • April 3, 2021 PDUFA for ACAD’s pimavanserin in DRP
  • Ph2 POC data for SRPT’s Phase 2 Gene Therapy for DMD in 1Q21
  • Ph3 MDD WATERFALL Data for SAGE’s zuranolone in 1H21
Cowen Research Themes 2021

View the Handbook